{"id":"https://openalex.org/W69345561","doi":"https://doi.org/10.2165/00023210-200418040-00005","title":"Dopamine Partial Agonists: A New Class of Antipsychotic","display_name":"Dopamine Partial Agonists: A New Class of Antipsychotic","publication_year":2004,"publication_date":"2004-01-01","ids":{"openalex":"https://openalex.org/W69345561","doi":"https://doi.org/10.2165/00023210-200418040-00005","mag":"69345561","pmid":"https://pubmed.ncbi.nlm.nih.gov/15015905"},"language":"en","primary_location":{"id":"doi:10.2165/00023210-200418040-00005","doi":"https://doi.org/10.2165/00023210-200418040-00005","is_oa":false,"landing_page_url":"https://doi.org/10.2165/00023210-200418040-00005","pdf_url":null,"source":{"id":"https://openalex.org/S153913659","display_name":"CNS Drugs","issn_l":"1172-7047","issn":["1172-7047","1179-1934"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W69345561"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075093461","display_name":"Jeffrey Alan Lieberman","orcid":"https://orcid.org/0000-0002-1899-1776","observed_orcids":["https://orcid.org/0000-0002-1899-1776"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jeffrey A Lieberman","raw_affiliation_strings":["University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7160, USA. jlieberman@unc.edu","University of North Carolina School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7160, USA. jlieberman@unc.edu","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"University of North Carolina School of Medicine","institution_ids":["https://openalex.org/I114027177"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5075093461"],"corresponding_institution_ids":["https://openalex.org/I114027177"],"apc_list":{"value":5090,"currency":"USD","value_usd":5090},"apc_paid":null,"fwci":2.9294,"has_fulltext":false,"cited_by_count":350,"citation_normalized_percentile":{"value":0.93410214,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"18","issue":"4","first_page":"251","last_page":"267"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.003800000064074993,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dopamine-partial-agonists","display_name":"partial dopamine agonist","score":0.984000027179718},{"id":"https://openalex.org/keywords/aripiprazole","display_name":"aripiprazole","score":0.9760000109672546},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.8059999942779541},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.7879999876022339},{"id":"https://openalex.org/keywords/dopamine-d2-receptor","display_name":"dopamine D2 receptor","score":0.7260000109672546},{"id":"https://openalex.org/keywords/5-ht1a-receptor","display_name":"5-HT1A receptor","score":0.8289999961853027},{"id":"https://openalex.org/keywords/5-ht2a-receptor-antagonism","display_name":"5-HT2A receptor antagonism","score":0.7960000038146973},{"id":"https://openalex.org/keywords/mesolimbic-dopamine-system","display_name":"mesolimbic dopamine system","score":0.8379999995231628},{"id":"https://openalex.org/keywords/mesocortical-dopamine-pathway","display_name":"mesocortical dopamine pathway","score":0.984000027179718},{"id":"https://openalex.org/keywords/negative-symptoms","display_name":"negative symptoms","score":0.7319999933242798},{"id":"https://openalex.org/keywords/extrapyramidal-symptoms","display_name":"extrapyramidal symptoms","score":0.8759999871253967},{"id":"https://openalex.org/keywords/hyperprolactinemia","display_name":"hyperprolactinemia","score":0.9940000176429749},{"id":"https://openalex.org/keywords/haloperidol","display_name":"haloperidol","score":0.7760000228881836},{"id":"https://openalex.org/keywords/schizoaffective-disorder","display_name":"schizoaffective disorder","score":0.8939999938011169},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.6639999747276306}],"concepts":[{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.9401418566703796},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.7680013179779053},{"id":"https://openalex.org/C2778258207","wikidata":"https://www.wikidata.org/wiki/Q600203","display_name":"Dopamine agonist","level":4,"score":0.5713037252426147},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.5576283931732178},{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.5419209599494934},{"id":"https://openalex.org/C38533456","wikidata":"https://www.wikidata.org/wiki/Q1671589","display_name":"Intrinsic activity","level":4,"score":0.5332828164100647},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.48944559693336487},{"id":"https://openalex.org/C160262196","wikidata":"https://www.wikidata.org/wiki/Q5376331","display_name":"Endogenous agonist","level":5,"score":0.4753415584564209},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4599868357181549},{"id":"https://openalex.org/C199596767","wikidata":"https://www.wikidata.org/wiki/Q21110872","display_name":"Dopamine receptor D3","level":4,"score":0.44952407479286194},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.44325560331344604},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.40604639053344727},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3423336148262024},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.306912362575531},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.25669458508491516},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.21568498015403748},{"id":"https://openalex.org/C120750228","wikidata":"https://www.wikidata.org/wiki/Q2035393","display_name":"Dopamine receptor D1","level":4,"score":0.20088940858840942},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.06861209869384766}],"mesh":[{"descriptor_ui":"D000068180","descriptor_name":"Aripiprazole","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004298","descriptor_name":"Dopamine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011618","descriptor_name":"Psychotic Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011618","descriptor_name":"Psychotic Disorders","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D012701","descriptor_name":"Serotonin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000145","qualifier_name":"classification","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.2165/00023210-200418040-00005","doi":"https://doi.org/10.2165/00023210-200418040-00005","is_oa":false,"landing_page_url":"https://doi.org/10.2165/00023210-200418040-00005","pdf_url":null,"source":{"id":"https://openalex.org/S153913659","display_name":"CNS Drugs","issn_l":"1172-7047","issn":["1172-7047","1179-1934"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Drugs","raw_type":"journal-article"},{"id":"pmid:15015905","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15015905","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":77,"referenced_works":["https://openalex.org/W45776812","https://openalex.org/W171492885","https://openalex.org/W1820626129","https://openalex.org/W1821305432","https://openalex.org/W1925492557","https://openalex.org/W1927413935","https://openalex.org/W1944617386","https://openalex.org/W1960419524","https://openalex.org/W1968700646","https://openalex.org/W1968837218","https://openalex.org/W1971179661","https://openalex.org/W1980235946","https://openalex.org/W1980980884","https://openalex.org/W1982205733","https://openalex.org/W1985058263","https://openalex.org/W1991558370","https://openalex.org/W2002689986","https://openalex.org/W2003708984","https://openalex.org/W2010741426","https://openalex.org/W2010764223","https://openalex.org/W2012410605","https://openalex.org/W2015246589","https://openalex.org/W2021398755","https://openalex.org/W2024913433","https://openalex.org/W2027336559","https://openalex.org/W2027466591","https://openalex.org/W2027826213","https://openalex.org/W2029267570","https://openalex.org/W2032208151","https://openalex.org/W2032469488","https://openalex.org/W2033155032","https://openalex.org/W2036534852","https://openalex.org/W2036668847","https://openalex.org/W2036918545","https://openalex.org/W2038409107","https://openalex.org/W2044469843","https://openalex.org/W2044960323","https://openalex.org/W2047174658","https://openalex.org/W2055001194","https://openalex.org/W2060393387","https://openalex.org/W2061544476","https://openalex.org/W2062389464","https://openalex.org/W2065432160","https://openalex.org/W2067763161","https://openalex.org/W2069849124","https://openalex.org/W2070357412","https://openalex.org/W2070895158","https://openalex.org/W2075028631","https://openalex.org/W2076704115","https://openalex.org/W2077767624","https://openalex.org/W2080671843","https://openalex.org/W2085609328","https://openalex.org/W2089763279","https://openalex.org/W2092416470","https://openalex.org/W2097126175","https://openalex.org/W2109481947","https://openalex.org/W2111105929","https://openalex.org/W2114801996","https://openalex.org/W2119478024","https://openalex.org/W2123354702","https://openalex.org/W2147024435","https://openalex.org/W2149148700","https://openalex.org/W2151331628","https://openalex.org/W2156035025","https://openalex.org/W2156197042","https://openalex.org/W2157574960","https://openalex.org/W2159472288","https://openalex.org/W2159996636","https://openalex.org/W2162046522","https://openalex.org/W2162707091","https://openalex.org/W2166770851","https://openalex.org/W2284323937","https://openalex.org/W2320983896","https://openalex.org/W2326588036","https://openalex.org/W2400995186","https://openalex.org/W2621028780","https://openalex.org/W4239785504"],"related_works":["https://openalex.org/W1993906767","https://openalex.org/W2160098367","https://openalex.org/W2392794121","https://openalex.org/W7099356552","https://openalex.org/W1996188218","https://openalex.org/W2036424845","https://openalex.org/W2080671843","https://openalex.org/W2352039749","https://openalex.org/W2106770968"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":18},{"year":2025,"cited_by_count":16},{"year":2024,"cited_by_count":10},{"year":2023,"cited_by_count":18},{"year":2022,"cited_by_count":17},{"year":2021,"cited_by_count":14},{"year":2020,"cited_by_count":16},{"year":2019,"cited_by_count":14},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":16},{"year":2015,"cited_by_count":11},{"year":2014,"cited_by_count":16},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":17}],"updated_date":"2026-11-15T12:55:33.944570","created_date":"2016-06-24T00:00:00"}
